الاقتصادية
الاقتصادية
Ready to play
Ready to play
The article discussed the price disparities of my medications Ozempic and Monjaro for obesity and diabetes treatment worldwide. The United States recorded the highest average monthly price at approximately $1,070, which is about 3.8 times higher than in Saudi Arabia, the cheapest among the compared countries, with an average of around $224. It was shown that pricing policies and the methodologies adopted in each country are the main reasons for this difference. Saudi Arabia links drug prices to a reference market of 16 countries and applies a uniform price for various dosages. In contrast, the U.S. market relies on higher prices and has historically not experienced major reductions, despite potential rumors of price cuts, with Ozempic expected to cost $675 starting in 2027. Europe has also seen price increases, especially in Britain, where Monjaro's price has increased by over 170% since September 2025. Meanwhile, Japan reduced drug prices by 25% in 2026. Alongside these changes, Saudi Arabia approved a new oral medication from Fonduao in August 2026, starting at a price of 517 SAR per dose, a move that accelerates market competition.
Notice: This Is an AI-Generated Summary
Comments (0)